The Medical Letter on Drugs and Therapeutics
Axitinib (Inlyta) for Advanced Renal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 6/5/12: In Table 1, footnote 2 has been removed from the cost of axitinib.

Axitinib (Inlyta – Pfizer), an oral tyrosine kinase inhibitor, has been approved by the FDA for treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. It is the fourth oral tyrosine kinase inhibitor to be approved for treatment of advanced renal cell carcinoma.1,2

STANDARD TREATMENT — Surgery is the preferred treatment for resectable renal cell cancer. Agents that prevent tumor angiogenesis and proliferation through inhibition of vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathways have now become the standard of care for unresectable or metastatic disease.3

Sunitinib is the most widely used tyrosine kinase inhibitor for initial treatment of advanced renal carcinoma, but no direct comparisons with other tyrosine kinase inhibitors are available. Everolimus ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Axitinib (Inlyta) for Advanced Renal Cell Carcinoma
Article code: 1392d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian